The Global X MSCI Greece ETF (GREK) has delivered a strong 25% return year-to-date, outperforming European and global peers by nearly double. Despite this, it still trades at a 25-40% discount in valuation. GREK's portfolio is heavily weighted toward financials, particularly Greek banks, which face challenges from a tough credit environment and higher loan loss provisions. Additionally, Greece's upcoming reclassification to developed market status could lead to net outflows and increased volatility for GREK holdings. While short-term momentum looks positive, long-term technical indicators suggest the ETF may be overextended. The analyst maintains a hold rating, noting the attractive valuation but warning of sector headwinds and risks from institutional flows.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
